Three strategies for articulating a coherent product value story
Translating brilliant science into a reimbursable, commercially competitive product is a multidisciplinary challenge, not just a scientific one. Articulating a coherent product value story from the start of development can help companies raise funds from investors, make smarter development decisions, gain market share, and win reimbursement.
This article covers our top three strategies to prime your product for commercial success.
Related Insights
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Blog
Investor-ready evidence planning: Why a robust strategy matters to funders
Dec 8, 2025
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Related Insights
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Blog
Investor-ready evidence planning: Why a robust strategy matters to funders
Dec 8, 2025
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023